Having screened for the optimal combination of ACK1/AKT inhibitors that yielded the lowest CI in the three KRAS-mutant NSCLC cell lines tested (NCI-H23, NCI-H358, and A549), we proceeded to evaluate the effect of the drug combinations on various cell behaviors. Here, TNK2 is linked to non-small cell lung carcinoma.